Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

381
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

188
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

A CLINICAL TRIAL OF NEOADJUVANT CONCURRENT CHEMORADIOTHERAPY FOLLOWED BY RESECTION FOR ESOPHAGEAL CARCINOMA

Pages

  751-756

Abstract

 Background: ESOPHAGEAL CARCINOMA is a common malignancy in the North East of Iran. Combined modality treatments have been adopted to improve SURVIVAL in patients with ESOPHAGEAL CARCINOMA. In this trial, we evaluated the efficacy and toxicity of a preoperative concurrent chemoradiotherapy protocol in the patients with locally advanced ESOPHAGEAL CARCINOMA.Materials and Methods: Between 2006 and 2011, eligible patients with locally advanced ESOPHAGEAL CARCINOMA underwent concurrent radiotherapy and chemotherapy and 3-4 weeks later, esophagectomy. Pathologic response, overall SURVIVAL rate, toxicity, and feasibility were evaluated.Results: One hundred ninety-seven patients with a median age of 59 (range: 27-70) entered the protocol. One hundred ninety-four cases (98.5%) had esophageal squamous cell carcinoma. Grades 3-4 of toxicity in patients undergoing neoadjuvant chemoradotherapy were as follows: Neutropenia in 21% and esophagitis in 2.5% of cases. There were 11 (5.6%) early death probably due to the treatment-related toxicities. One hundred twenty-seven patients underwent surgery with postsurgical mortality of 11%.In these cases, the complete pathological response was shown in 38 cases (29.9%) with a 5-year overall SURVIVAL rates of 48.2% and median overall SURVIVAL of 44 months (95% confidence interval, 24.46-63.54).Conclusion: The pathological response rate and the overall SURVIVAL rate are promising in patients who completed the protocol as receiving at least one cycle of chemotherapy. However, the treatment toxicities were relatively high.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    ANVARI, KAZEM, ALEDAVOOD, SEYED AMIR, SEILANIAN TOUSSI, MEHDI, FORGHANI, MOHAMAD NASER, MOHTASHAMI, SAMIRA, RAJABI, MOHAMMAD TAGHI, HOMAEE SHANDIZ, FATEMEH, NOSRATI, FATEMEH, NOFERESTI, GHOLAMHOSSEIN, & SALEK, ROHAM. (2015). A CLINICAL TRIAL OF NEOADJUVANT CONCURRENT CHEMORADIOTHERAPY FOLLOWED BY RESECTION FOR ESOPHAGEAL CARCINOMA. JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS), 20(8), 751-756. SID. https://sid.ir/paper/668067/en

    Vancouver: Copy

    ANVARI KAZEM, ALEDAVOOD SEYED AMIR, SEILANIAN TOUSSI MEHDI, FORGHANI MOHAMAD NASER, MOHTASHAMI SAMIRA, RAJABI MOHAMMAD TAGHI, HOMAEE SHANDIZ FATEMEH, NOSRATI FATEMEH, NOFERESTI GHOLAMHOSSEIN, SALEK ROHAM. A CLINICAL TRIAL OF NEOADJUVANT CONCURRENT CHEMORADIOTHERAPY FOLLOWED BY RESECTION FOR ESOPHAGEAL CARCINOMA. JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS)[Internet]. 2015;20(8):751-756. Available from: https://sid.ir/paper/668067/en

    IEEE: Copy

    KAZEM ANVARI, SEYED AMIR ALEDAVOOD, MEHDI SEILANIAN TOUSSI, MOHAMAD NASER FORGHANI, SAMIRA MOHTASHAMI, MOHAMMAD TAGHI RAJABI, FATEMEH HOMAEE SHANDIZ, FATEMEH NOSRATI, GHOLAMHOSSEIN NOFERESTI, and ROHAM SALEK, “A CLINICAL TRIAL OF NEOADJUVANT CONCURRENT CHEMORADIOTHERAPY FOLLOWED BY RESECTION FOR ESOPHAGEAL CARCINOMA,” JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS), vol. 20, no. 8, pp. 751–756, 2015, [Online]. Available: https://sid.ir/paper/668067/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top